Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 6/20 | 0.44 |
| ▸ | CES1 | P23141 | 6/20 | 0.44 |
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | LOX | P28300 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SPR | P35270 | 1/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA4 | P22748 | 2/20 | 0.36 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29810617 | 0.97 | CES2 (0.43) | CES2CES1PARP1ERN1MAOA | |
| SCHEMBL147636 | 0.86 | CES2 (0.39) | CES2CES1PARP1ERN1MAOA | |
| SCHEMBL1718375 | 0.84 | DGAT1 (0.41) | CES2CES1PARP1ERN1MAOA | |
| SCHEMBL4163281 | 0.84 | GRM2 (0.38) | CES2CES1PARP1ERN1MAOA | |
| SCHEMBL811633 | 0.82 | PARP1 (0.45) | CES2CES1PARP1ERN1DGAT1 | |
| SCHEMBL4262805 | 0.82 | DGAT1 (0.38) | CES2CES1PARP1DGAT1KMT2A | |
| SCHEMBL1317647 | 0.80 | DGAT1 (0.55) | PARP1DGAT1GAAKMT2AMAP2K1 | |
| SCHEMBL12121150 | 0.80 | POLB (0.41) | PARP1DGAT1KMT2AMAP2K1 | |
| SCHEMBL3024877 | 0.80 | GRM2 (0.42) | PARP1DGAT1GAASPR | |
| Hydrochloric Acid SCHEMBL17629791 | 0.80 | DGAT1 (0.36) | CES2CES1PARP1DGAT1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120044163-A | HPLC analysis and detection method for 2,4, 6-trifluoro benzoyl chloride and related substances thereof | 复星万邦(江苏)医药集团有限公司 | 2025-05-27 | — | — | CN | claimed |
| CN-114144408-B | Large scale preparation of 2,4, 6-trifluoro-N- [6- (1-methyl-piperidine-4-carbonyl) -pyridin-2-yl ] -benzamide hemisuccinate and process and intermediates for preparing 2,4, 6-trifluoro-N- [6- (1-methyl-piperidine-4-carbonyl) -pyridin-2-yl ] -benzamide acetate | 伊莱利利公司 | 2025-04-15 | — | — | CN | claimed |
| EP-3996713-B1 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE | LILLY CO ELI (US) | 2024-12-04 | — | — | EP | claimed |
| EP-4465988-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS | Calcimedica, Inc. (US) | 2024-11-27 | — | — | EP | claimed |
| CN-118994035-A | Organic electroluminescent material based on aza-aryl spirobifluorene | 四川大学 | 2024-11-22 | — | — | CN | claimed |
| EP-4410784-A2 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE | Eli Lilly and Company (US) | 2024-08-07 | — | — | EP | claimed |
| US-20240059666-A1 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE | ELI LILLY AND COMPANY | 2024-02-22 | — | — | US | claimed |
| US-20230250075-A1 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE | ELI LILLY AND COMPANY | 2023-08-10 | — | — | US | claimed |
| US-20230250076-A1 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE | ELI LILLY AND COMPANY | 2023-08-10 | — | — | US | claimed |
| WO-2023141523-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS | CALCIMEDICA, INC. (US) | 2023-07-27 | — | — | WO | claimed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| US-20050032795-A1 | 2-Amino-benzoxazinones for the treatment of herpes simplex virus | G.D. SEARLE & CO. (US) | 2005-02-10 | — | — | US | claimed |
| EP-1086106-B1 | FUROPYRIDINE DERIVATIVES AND THEIR THERAPEUTICAL USE | DARWIN DISCOVERY LTD (GB) | 2003-08-20 | — | — | EP | claimed |
| WO-2002028353-A2 | PHOSPHATE TRANSPORT INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-04-11 | — | — | WO | claimed |
| EP-1086106-A1 | FUROPYRIDINE DERIVATIVES AND THEIR THERAPEUTICAL USE | Darwin Discovery Limited (GB) | 2001-03-28 | — | — | EP | claimed |
| US-6169090-B1 | FOR INHIBITION OF PHOSPHODIESTERASE IV | DARWIN DISCOVERY, LTD. (GB) | 2001-01-02 | — | — | US | claimed |
| WO-1999064423-A1 | FUROPYRIDINE DERIVATIVES AND THEIR THERAPEUTICAL USE | DARWIN DISCOVERY LIMITED (GB) | 1999-12-16 | — | — | WO | claimed |
| WO-1993014062-A1 | ANTHELMINTIC β-KETOAMIDES | THE UPJOHN COMPANY (US) | 1993-07-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059666-A1 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE | LPXN, KDM2A, PMP22 | CES2 379/4885CES1 306/4885PARP1 1621/4885 |
| US-20230250075-A1 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE | LPXN, KDM2A, PMP22 | CES2 379/4885CES1 306/4885PARP1 1621/4885 |
| US-20050032795-A1 | 2-Amino-benzoxazinones for the treatment of herpes simplex virus | GABBR1, GABBR2, EBNA1BP2 | CES2 1056/4885CES1 2805/4885PARP1 3217/4885 |
| US-20230250076-A1 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE | LPXN, KDM2A, PMP22 | CES2 379/4885CES1 306/4885PARP1 1621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.